Table 1. Patient characteristics.
| Number of patients | 52 |
| Gender (n (% of study population)) | |
| Male | 24 (46.2%) |
| Female | 28 (53.8%) |
| Median age at MMF start (years) | 13 (range: 3–18) |
| Median disease duration prior to MMF therapy (months) | 15.5 (range: 2–132) |
| Median duration of MMF therapy (months) | 27 (range: 0.5–50) |
| Median follow-up time after MMF start (months) | 33 (range: 6–53) |
| Diagnosis (n (% of study population)) | |
| JIA anterior uveitis | 25 (48.1%) |
| Idiopathic intermediate uveitis | 9 (17.3%) |
| Idiopathic anterior uveitis | 8 (15.4%) |
| Idiopathic panuveitis | 5 (9.6%) |
| Idiopathic posterior uveitis | 2 (3.8%) |
| Sarcoidosis anterior uveitis | 1 (1.9%) |
| TINU anterior uveitis | 1 (1.9%) |
| Sympathetic ophthalmia panuveitis | 1 (1.9%) |
| Disease laterality (n (% of study population)) | |
| Unilateral | 12 (23.1%) |
| Bilateral | 40 (76.9%) |
| Previous steroid-sparing IMTs (n (% of study population)) | |
| None | 4 (7.7%) |
| Methotrexate | 48 (92.3%) |
| Cyclosporine | 4 (7.7%) |
| Adalimumab | 2 (3.8%) |
| Infliximab | 2 (3.8%) |
| Etanercept | 1 (1.9%) |
Abbreviations: IMT, immunomodulatory therapy; JIA, juvenile idiopathic arthritis; MMF, mycophenolate mofetil; TINU, tubulointerstitial nephritis and uveitis syndrome.